Lymphoma Clinical Trials

Showing 1741-1760 of 2,926 trials

Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

NCT00182637

RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with relapsed or refractory cutaneous T-cell lymphoma.

Lymphoma

Jonsson Comprehensive Cancer Center5 participantsStarted Jul 2004

Los Angeles, California, United States

TERMINATED

Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy

NCT01319526

RATIONALE: Studying samples of blood in the laboratory from patients undergoing treatment with HIV infection and Hodgkin lymphoma may help doctors learn more about the effects of therapy on HIV. PURPOSE: This research study is studying biomarkers in blood samples from patients with HIV infection and stage III or stage IV Hodgkin lymphoma undergoing chemotherapy.

LymphomaNonneoplastic Condition

AIDS Malignancy Consortium1 participantsStarted Jun 2011

Baltimore, Maryland, United States • Boston, Massachusetts, United States

UNKNOWNPhase 4

A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma

NCT04490590

To observe the safety, tolerability and clinical effects of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma.

NK/T-Cell Lymphoma

Mingzhi Zhang30 participantsStarted Oct 2016

Zhengzhou, Henan, China

UNKNOWNPhase 1/2

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

NCT03778619

To determine the efficacy and safety of combined therapy of determined MG4101 dose and Rituximab.

Relapsed Non Hodgkin LymphomaRefractory Non-Hodgkin Lymphoma

GC Cell Corporation9 participantsStarted Nov 2018

Seoul, South Korea • Seoul, South Korea • Seoul, South Korea

Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy

A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

Related Searches

Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell Lymphoma

A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas

Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

Multi-CAR-T Cells Targeting B Cell Lymphomas

Study of GLS-010 Injection in the Treatment of Classical Hodgkin's Lymphoma

Atrial Fibrillation in Patients Receiving Ibrutinib

Predictive Value of a mRNA Signature and Liquid Biopsy in Diffuse Large B Cell Lymphoma

R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

Reduced Radiation in Patients With Diffuse Large B-cell Lymphoma

A Study of GC022F CAR-T Cell Immunotherapy for Relapsed or Refractory B- NHL

GPED Regimen for Relapsed/Refractory or Advanced ENKTCL

Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials